3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
200
Other hematologic neoplasm
54
Plasma cell
26
Dermatologic
25
Myeloid
23
CNS
14
Sarcoma
11
Gynecologic
11
Genitourinary
10
Breast
10
Other neoplasm
8
Classical hematology
8
Thoracic
2
Gastrointestinal
2
Endocrine
2
Other solid neoplasm
1
NET
1
Head & Neck
1
Conditions
Neuroendocrine Tumors
32
Gastro-enteropancreatic neuroendocrine tumor
6
Carcinoid Tumor
4
Adenoma, Islet Cell
3
Serotonin Syndrome
2
Parkinson Disease
2
Neuroblastoma
2
Neoplasms
2
Congenital Hyperinsulinism
2
Advanced Gastroenteropancreatic Neuroendocrine Tumor
2
Thymus Neoplasms
1
Pancreatic Neuroendocrine Tumors in MEN1
1
Pancreatic Neuroendocrine Tumors (pNET)
1
Non functioning pancreatic endocrine tumor
1
Neuroendocrine Tumors in Lung
1
Neuroectodermal Tumors, Primitive
1
Neoplasm Metastasis
1
Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms
1
Lymphoma, Follicular
1
Liposarcoma
1
Lewy Body Disease
1
Insulinoma
1
Hypoglycemia
1
Hyperinsulinism
1
Flushing
1
Fibrosarcoma
1
Disease
1
Digestive Neuroendocrine Tumors
1
Diarrhea
1
Carcinoid Tumors, Intestinal
1
Interventions
pasireotide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoma, Follicular
×
NET
×
Clear all
NCT06784752
2026-04-30
NETTER-3
Novartis
Phase 3
Recruiting
240 enrolled